About olema pharmaceuticals inc - OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
OLMA At a Glance
Olema Pharmaceuticals, Inc.
780 Brannan Street
San Francisco, California 94103
| Phone | 1-415-651-3316 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -129,474,000.00 | |
| Sector | Health Technology | Employees | 96 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
OLMA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.059 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.636 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.016 |
OLMA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,348,687.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
OLMA Liquidity
| Current Ratio | 10.50 |
| Quick Ratio | 10.50 |
| Cash Ratio | 10.395 |
OLMA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -31.086 |
| Return on Equity | -39.065 |
| Return on Total Capital | -31.549 |
| Return on Invested Capital | -38.966 |
OLMA Capital Structure
| Total Debt to Total Equity | 0.349 |
| Total Debt to Total Capital | 0.348 |
| Total Debt to Total Assets | 0.257 |
| Long-Term Debt to Equity | 0.063 |
| Long-Term Debt to Total Capital | 0.063 |